A deep molecular dive into COVID-19 patients found that the presence of autoantibodies in peripheral blood at initial diagnosis was the chief of four risk factors predicting if a patient would experience long COVID.
Computer analysis of human brain immune components showed that NRP1 and furin were significantly expressed in neuronal cells, suggesting that NRP1 may have a role in SARS-CoV-2 neuropathology.
This article aims to summarize the latest research on how rituximab affects humoral and cell-mediated response after a COVID-19 vaccine primary series, and whether a booster changes patient response.